

Disclosure Purpose: 22-02879

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02879

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
BlueDot	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Consultant
NHL Players' Association	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> COVID safety protocols

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-02879

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-02879

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02879

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02879

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02879

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-02879

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Providence Therapeutics	Grant / Contract	Self
<i>Recipient Name:</i> Anne-Claude Gingras <i>Grant / Contract Description:</i> Our team has helped (based on service-contract) to analyze antibody levels in preclinical and phase		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02879

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults

3. **Are you the corresponding author?**

Yes.

a. **Please list the other authors' names here.**

Patrick E. Brown, Ph.D. Sze Hang Fu, M.S.A. Aiyush Bansal, M.D. Leslie Newcombe, B.Sc. Karen Colwill, Ph.D. Geneviève Mailhot, M.Sc. Melanie Delgado-Brand, B.Sc. Anne-Claude Gingras, Ph.D., Arthur S. Slutsky, M.D. Maria Pasic, Ph.D. Jeffrey Companion Isaac I. Bogoch, M.D. Ed Morawski, M.A. Teresa Lam, B.A. Angus Reid, Ph.D.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-02879

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-02879

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02879

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02879

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02879

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-02879

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02879

Summary of Interests

Entity	Type	Interest Held By
Altimmune	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Consultant re drug for COVID-19
Cellenkos	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Diffusion Pharmaceuticals	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Consultant re drug for COVID-19
Faron	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i>		<i>Description:</i>
GlaxoSmithKline	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Consultant re drug for COVID-19

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Omicron (BA.1/1.1) SARS-CoV-2 Infection among Vaccinated Canadian Adults
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.